KY-226

KY-266 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B, IC50 = 0. µM). It enhances insulin-induced phosphorylation of insulin receptors in HepG2 cells when used at concentrations of 1, 3, and 10 µM. In vivo, KY-266 (10 and 30 mg/kg) reduces plasma glucose and triglyceride levels and hemoglobin A1c (HbA1c) levels in db/db mice. It decreases body weight gain, food intake, and fat volume gain in a mouse model of high-fat diet-induced obesity when administered at 30 and 60 mg/kg per day for four weeks. Intraperitoneal administration of KY-226 (10 mg/kg) restores Akt phosphorylation and reduces cortical reactive oxygen species (ROS) production in a mouse model of ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO). InChI: InChI=1S/C27H31NO3S2/c1-2-3-4-8-19-33(30,31)28-27(29)26-17-13-23(14-18-26)21-32-20-22-11-15-25(16-12-22)24-9-6-5-7-10-24/h5-7,9-18H,2-4,8,19-21H2,1H3,(H,28,29) InChIKey: MKXMABKUVSOEJF-UHFFFAOYSA-N SMILES: O=C(C1=CC=C(CSCC2=CC=C(C3=CC=CC=C3)C=C2)C=C1)NS(=O)(CCCCCC)=O